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Abstract
Background: The present study aimed to explore and compare inflammatory bowel disease (IBD) and functional gastrointestinal disorders (FGiDs) patients’ experiences with and attitudes towards psychotherapy and antidepressants.
Methods: Patients from gastroenterology clinic databases were invited to an online survey. Student t-test, Mann-Whitney test, chi-square test and Fisher’s test were used to compare patients with IBD and FGiD on demographics and variables of interest. 
Results: Of 86 participants, 56 (65%) had IBD and 30 (35%) FGiDs. Mean levels of anxiety, depressive and stress symptoms were within the moderate to severe range. Psychological care and antidepressants were offered to significantly more FGiD than IBD respondents (37% vs. 9%, p=.009). Although the symptoms antidepressants were prescribed for generally improved, only 30% of IBD and 21% of FGiD respondents using antidepressants would recommend them to others. In contrast, 53% of IBD and 69% of FGiD respondents who used psychotherapy would recommend it to others. Both these therapies were valued by recipients, however, neither was reported to improve GI symptoms. 
Conclusions: Given the high desire for and positive experiences of psychological care for these two common GI conditions, access to formal psychological support services within GI clinics would appear to be the most efficient model.
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Introduction
Inflammatory bowel disease (IBD) is a group of chronic, relapsing inflammatory disorders of the gut, usually diagnosed in young adults, with sufferers therefore affected for many years (). In Australia alone, the incidence of IBD is 29.3 per 100,000 (95% confidence interval [CI] 23.5-36.7)  ADDIN EN.CITE () and there are currently over 70,000 IBD sufferers, with this number expected to increase by 20% by 2020 (). The course of the disease varies between patients and by and large is unpredictable. IBD is characterised by an inappropriate immune response causing characteristic inflammatory lesions in the gut wall. While the aetiology of IBD is unknown, genetic, immune and environmental factors are all implicated. More recently psychological status has also been found to influence the timing of disease relapse () and hospitalisation rates (). 

Studies show 30% rate of depression during IBD remission (). There is a controversy regarding whether there is any specific efficacy of psychotherapy and antidepressants in IBD in relation to inflammatory disease activity although there is more certainty on their positive role in improving mood (). It is also unknown whether IBD patients are open to the co-morbid mental disorders or their bowel symptoms being managed (even in part) with antidepressants and/or psychotherapy, with only one study to date examining acceptance of antidepressant treatment in IBD (). Thus, the present study is seeking to fill this gap in knowledge regarding patient acceptability and perceived efficacy.

Functional Gastrointestinal Disorders (FGiDs) are disorders of the gastrointestinal (GI) tract that are incompletely understood pathologically and are diagnosed positively based on symptom clusters and exclusion of common differential diagnoses (). FGiDs are made up of particular combinations of symptoms which are thought to result from enhanced visceral hypersensitivity, altered mucosal immune and inflammatory responses and altered central nervous system-enteric nervous system interplay (). 

FGiDs comprise a major portion of clinical practice for gastroenterologists () as well as being significant in the wider health care system in terms of prevalence and cost. Psychological factors are important in considering the nature and treatment of FGiDs and psychological disorders such as anxiety and depression are highly prevalent in FGiD patients (). As compared to IBD, there is high level evidence for efficacy of antidepressants and psychotherapy in FGiDs, with the recent meta-analysis by Ford et al. () reporting a reduction in FGiDs symptoms for both antidepressants and psychological therapies. However, there is little data examining patients’ attitudes towards these therapies. Thus, the present study aims to explore this, by conducting a survey on patients’ views and experiences with antidepressants and psychotherapy and by comparing responses from IBD and FGiD respondents.

Materials and Methods
Design and participants
A cross-sectional online survey was conducted. Participants were recruited from the clinical databases of the gastroenterology clinic within a large tertiary teaching hospital in Adelaide, South Australia, serving a local referral population of approx. 600,000 and also providing state-based specialty services for an additional 300–400,000 people. 

Inclusion criteria
Patients were included in the survey if they: 
- had a diagnosis of either FGIDs or IBD made by a clinic gastroenterologist based on endoscopy and/or report;
- were on either of the databases;
- consented to participate in the study.

Exclusion criteria
Patients were excluded from the survey if they:
- were younger than 18 years of age;
- had no access to Internet as the study was conducted exclusively online.

Sample size
Sample size was not formally calculated as the study was exploratory in nature and did not aim to test any hypothesis. Nevertheless, an assumption was made that a sample of approximately 100 participants would be recruited based on a typical low response rate to surveys advertised via post or electronically. In particular, 2012 letters were sent to FGiD patients and 608 to IBD patients, of which approx. 200 were returned due to changed address.

Procedure 
The study was advertised through emails and letters sent to patients in October 2012. The letters/emails contained the participant information sheet and the link to the survey. The interested patients consented to participate and answered the survey directly through this link. Survey Monkey() was used as it allows confidential access and facilitates data analysis. After finishing the survey participant responses were automatically summarised and available to the researchers. Data were then analysed. No incentive was offered for survey completion.

Measurement
The survey was anonymous and asked about demographics, previous experiences using antidepressants and psychotherapy (any talk therapy) and about current mental health status along with willingness to use antidepressants and participate in psychotherapy programs in the future. An example question is: ‘I would be willing to use pharmacological drug support such as antidepressants or other medications prescribed by a general practitioner, psychiatrist, or other doctor’, which was measured on a 5-point Likert scale (strongly agree to strongly disagree). The survey also included the Depression Anxiety Stress Scale (DASS-21) which is a widely used measure of mental health. The factor structure, reliability, and validity of the DASS-21 are well established ().

Outcome measures
Main outcome measures were: 1) Patients’ experiences using antidepressants and psychotherapy for their GI complaints and psychological problems, and 2) Patients’ attitudes towards the future use of antidepressants and psychotherapy.

Statistical analysis
Numerical results of the survey were summarised using descriptive statistics, with means, standard deviations, median, inter-quartile ranges and percentages presented. Normality was tested using the qq plots. Groups were compared using the student t-test for continuous normally distributed variables and the Mann-Whitney test for continuous not normally distributed data. Categorical data were compared with the chi-square test or Fisher’s test depending on the number of cells. The two-sided significance level was set at 0.05.

Ethics approval
The study was approved by the Hospital Research Ethics Committee (120905) and the University Human Research Ethics Committee (0000030753) in September 2012. Participants gave informed consent and patient anonymity was preserved. 

Results
Demographics
Overall, 92 patients participated in this online survey. However, six of these had to be removed from the analysis as the provided data were largely incomplete. Thus, the final sample was 86, 56 (65%) of which had IBD and 30 (35%) FGiD. Among FGiD sufferers, 10 (11%) reported irritable bowel syndrome (IBS), 13 (14%) - undiagnosed functional disorder, five (5%) - reflux, two (2%) - functional dyspepsia, and one (1%) a functional biliary disorder. Demographic characteristics are presented in Table 1. 

INSERT TABLE 1
Control of physical symptoms
When asked about how well controlled their GI condition had been, 68 (79%) reported it to be either well or reasonably controlled. However, the groups differed in their perception of disease control, with more IBD respondents reporting well controlled disease (45% vs. 23%), and fewer IBD respondents reporting poor disease control than FGiD respondents (9% vs. 30%) (p=.022).

Current mental health status
IBD and FGiD respondents did not differ in their mean symptom score for depression (9.7 (SD=10.7) vs. 12.4 (SD=10.6) consistent with moderate to severe depressive symptoms), anxiety (7.1 (SD=6.9) vs. 8.9 (SD=8.7), consistent with moderate to severe anxiety symptoms) or stress (13.3 (SD=10.1) vs. 14.7 (SD=10.1) (p>0.05), consistent with severe stress). 

General GI management
Overall, 53 (62%) respondents reported high satisfaction with the current management of their GI condition; however, the groups differed in their satisfaction with GI treatment. Significantly more IBD respondents reported high satisfaction with their GI treatment than FGiD respondents (56/77% vs. 10/33%, p=.001).

Experience with psychotherapy and antidepressants use in general
Table 2 demonstrates that more FGiD respondents than IBD had received psychotherapy or antidepressants. The difference was particularly high in rates of psychological support or counselling received from the GP (p<0.001) but also in the rates of use of antidepressants prescribed by a psychiatrist (p=.002), other doctor (p=.005), or a GP (p=.022). FGiD participants had also received more psychological support from a psychiatrist (p=.023), psychologist (p=.027) and self-help booklet-based (p=.042).

INSERT TABLE 2
More FGiD than IBD respondents had received antidepressants (p=.042) and twice as many had experienced antidepressant-related side-effects (p=.018) (Table 3). Although the symptoms antidepressants were to target had generally improved, only 30% of IBD and 21% of FGiD respondents who had used antidepressants would recommend this treatment to other patients. In contrast, 53% of IBD respondents and 69% of FGiD respondents who had used psychotherapy would recommend it to others. In the vast majority of cases, the GI condition had reportedly remained unaffected by the antidepressant (no change in GI condition reported by 73% of IBD and 79% of FGiD respondents) or psychotherapy (no change in GI condition reported by 79% of IBD and 87% of FGiD respondents) use while mood had almost universally improved. In particular, 73% of IBD respondents and 73% of FGiD respondents reported improved mood after having received antidepressants and 57% of IBD respondents and 79% FGiD respondents reported improved mood using psychotherapy. The latter difference, although numerically large, was not statistically significant, most likely as there were few respondents in each category.
INSERT TABLE 3

Psychological care before and after the GI diagnosis
The majority of respondents reported they had not been offered psychological care before or after the GI diagnosis and were in accord that this should not have been offered to them. However, a significant minority (17% before the GI diagnosis and 27% after the GI diagnosis) reported that such help had not been offered but would have been welcome (Table 4). When characteristics of this group were explored in comparison to respondents who had not expressed such an opinion, respondents who reported they should have been offered psychological help and had not been offered it were significantly younger in the before GI diagnosis group (p=.042). 

In addition, there was a significant group difference (p=.009) in the pre-diagnosis experience with psychological care (Table 4). Significantly more FGiD respondents had been offered and accepted such service. However, 50% more IBD respondents had not been offered the service and wished it to be offered to them before the GI diagnosis. 

INSERT TABLE 4

Attitudes towards psychotherapy and antidepressants
In both IBD and FGID patients, the preference towards one-on-one psychotherapy was noticeable (Table 5), with the least preferred option being group psychotherapy or antidepressants. 
INSERT TABLE 5
In the sample as a whole, 43 (50%) respondents reported that they would be willing to try any type of psychological support offered (55% of IBD vs. 40% FGiD). Further, there were more respondents willing to use pharmacological treatment (i.e. antidepressants) than not using it (44% vs. 36%). Numerically more FGiD respondents would be willing to use drug treatment than IBD respondents (47% vs. 43%). Sixty-five percent (n=56) were willing to use one-on-one psychotherapy (66% of IBD vs. 63% of FGiD). Forty five percent (n=39) were willing to use internet psychotherapy (48% of IBD vs. 40% of FGiD) while 56% (n=48) were willing to use a booklet-based psychotherapy (57% of IBD vs. 53% of FGiD). In contrast, only 29 (34%) respondents were willing to participate in group therapy should such therapy be offered (34% of IBD vs. 33% of FGiD). 

When asked about frequency of sessions, the majority of respondents providing an answer to this question (n=41, 48%) had preferred weekly sessions. Shorter therapies: 10-12 weeks were preferred by 10 (12%) respondents; 6-8 weeks were preferred by 11 (13%) respondents; 4-5 weeks by eight (9%) respondents, with the remaining respondents unsure of the preferred length. 

Discussion
This online survey is one of the few studies to explore patients’ attitudes towards antidepressants and psychotherapy in IBD and FGiDs. Both antidepressants and psychotherapy are widely used in the two conditions, although the evidence for their efficacy is far stronger in FGiDs than in IBD. Surprisingly, despite their widespread use, attitudes towards psychotherapy and antidepressants treatment in the GI populations have not been explored in quantitative studies to date. Previous qualitative studies with small groups of IBD sufferers on their attitudes to psychotherapy () and antidepressants () have suggested that psychotherapy is underused in IBD and that both psychotherapy and antidepressants appear to ameliorate the disease course, at least in some patients. The recommendation from qualitative exploratory studies was to conduct larger quantitative research on patient experiences and attitudes in relation to psychotherapy and antidepressants; hence the present survey.

The most interesting finding of this study was that the majority of respondents who had used psychotherapy would recommend it to others. The majority also reported that psychotherapy improved the symptoms it had been prescribed for, highlighting the significant role of psychotherapy and psychological counselling in treatment of these groups of patients. In contrast, although the symptoms antidepressants had been prescribed for generally improved, only up to one third of respondents who had used antidepressants would recommend this treatment to other patients. These numbers, of course, should be treated with caution as the percentage of the total sample who had experience using psychotherapy and antidepressants was relatively low. Nonetheless, these trends are important and should be borne in mind in guiding the design of services for GI patients and could guide gastroenterology nurses in their practice with these patients.

Further, FGiD respondents reported a significantly higher rate of antidepressant-related side-effects and have used antidepressants more commonly than IBD respondents and so a greater exposure and negative experiences may explain this attitude. Also, FGID patients are frequently prescribed antidepressants to help with their somatic symptoms (), yet in the present study participants’ GI symptoms reportedly remained unchanged during antidepressant or psychotherapy which is likely to have contributed to the negative attitude towards them by FGiD respondents. Despite this negative perception, in the whole sample, antidepressants had more supporters than opponents, and numerically more FGiD respondents reported willingness to use drug treatment than IBD respondents.

In terms of the preference for particular psychotherapies, the most highly preferred mode of therapy was individual one-on-one psychotherapy and the least favoured was group psychotherapy. This may perhaps be explained by the stigma associated with bowel conditions (). This finding may also have implications for service delivery as one-on-one psychotherapy, although preferred by patients, is the most costly of therapies. However, an encouraging finding is a sound support for online and booklet-based psychotherapies, which may offer more cost-effective therapeutic solutions while providing patients with privacy, and which can be delivered by trained nurses instead of or in addition to psychologists. The comparative efficacy of such methods is yet to be established specifically in IBD, however, systematic reviews of the general mental health populations report similar efficacy for online therapies  ADDIN EN.CITE (; ). 

Perhaps unsurprisingly, given their aetiology and the well-established link between symptoms of FGiDs and mental health problems, a greater number of FGiD than IBD patients had utilised psychotherapy or antidepressants. Yet, in contrast to a previous study (), in the present study there was no significant mean difference in depressive, anxiety and stress symptoms and thus current mental health status alone could not justify this referral pattern. 

One of the reasons for the present study was to explore whether patients receive the mental health care they need, and whether they would be accepting of such care, if services were made available for them. Clearly, IBD patients’ access to psychological help was less than that of FGiD respondents. Moreover, this was not simply due to patient preference, as over 30% of them had indicated that they believed they should have been offered access to a mental health provider after IBD diagnosis and over 20% believed such help should have been available to them before the diagnosis. This is a clear sign of an ongoing and unmet mental health need, although from the analysis it is unclear which patients constitute this group as they did not differ in demographics (with the exception of age) or mental health status to respondents who did not believe such help should have been offered. Future studies should attempt to identify this group of patients in need, perhaps by including more in-depth personality and mental health status measures. 

Amongst respondents, those with FGiD received more counselling from a GP and other health professionals than IBD respondents, and more often had received antidepressants from various specialists, perhaps suggesting a greater awareness among health professionals of the psychological burden associated with FGiDs and, in contrast, a lack of awareness of the high prevalence of psychological difficulties in the IBD community. Future studies could focus on promotion of knowledge on mental health in IBD patients among GPs since they are the primary mental health providers to chronic disease sufferers in Australia.

Limitations
The limitations of the present study, similarly to other survey-based research, must be acknowledged. The participation bias (only those with access to the Internet), reliance on self-report and potential recall bias when asked to report on disease course while taking antidepressants / receiving psychotherapy, are all important to consider. In addition, the majority of respondents reported well managed conditions which may be an indication of good quality care provided by the hospital, however, it is also possible that people not satisfied with care did not participate in the survey and thus the findings may not be generalizable to these patients. In addition, patients who responded to the survey may have been more interested in mental health, with greater problems in this regard than non-respondents as the study was openly introduced as a survey on attitudes to antidepressants and psychotherapy, and the rates of anxiety, depressive and stress symptoms within the moderate to severe range confirm this hypothesis. Further, due to the anonymous nature of the study it was not possible to compare responders and non-responders and such a comparison could shed some light on whether these participants are representative of the larger Australian IBD and FGiD population, particularly that as predicted a response rate for the study was low. Last but not least, although the study observed high rates of satisfaction with psychotherapy and low with antidepressants, the numbers of respondents who had experience with these therapies were relatively small and thus these observations should be interpreted with caution as they may not be representative of the larger GI population.
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Tables
Table 1: Demographic and clinical characteristics
	IBDn=56	FGiDn=30	Totaln=86
	n (%)
Female	28 (50)	20 (67)	48 (56)
Married/ partnered	32 (59)	14 (47)	46 (53)
Working full-time	19 (34)	8 (27)	27 (31)
Completed university degree	17 (30)	11 (37)	28 (32)
Private health insurance 	26 (47)	13 (45)	39 (45)
Speak language other than English at home	5 (9)	3 (10)	8 (9)
Take medication for GI symptoms	48 (86)**	12 (41)	60 (70)
Take analgesics	21 (38)	15 (52)	36 (42)
Had operations or procedures for their GI condition	39 (70)	15 (52)	54 (63)
Hospitalised for their GI condition	45 (83)**	9 (31)	54 (63)
Other chronic illness	29 (52)	19 (65)	48 (56)
	Mean (SD)
Age	39.6 (14.7)*	48.2 (15.1)	42.69 (15.34)# 
Time since diagnosis	10.6 (8.2)	6.8 (5.9)	9.5 (7.8)
*p<.05, **p<.001
# Age ranged from 19 to 74 years 


Table 2: Experience with psychological / psychiatric services by disease type
		IBDn=56	FGiDn=30
		n (%)
Pharmacological support such as antidepressants prescribed by general practitioner	Received*	21 (37)	17 (57)
	Satisfied	9 (16)	9 (30)
	Not satisfied	3 (5)	6 (20)
Pharmacological support such as antidepressants prescribed by psychiatrist	Received**	13 (23)	14 (47)
	Satisfied	6 (11)	7 (23)
	Not satisfied	0	5 (17)
Pharmacological support such as antidepressants prescribed by another doctor	Received**	10 (18)	10 (33)
	Satisfied	0	2 (7)
	Not satisfied	2 (4)	6 (20)
Psychological support  or counselling from psychologist	Received *	17 (30)	17 (57)
	Satisfied	7 (12)	6 (20)
	Not satisfied	6 (11)	6 (20)
Psychological support  or counselling from psychiatrist	Received*	59 (27)	15 (50)
	Satisfied	7 (12)	5 (17)
	Not satisfied	2 (4)	4 (13)
Psychological support  or counselling from general practitioner	Received***	15 (27)	18 (60)
	Satisfied	5 (9)	9 (30)
	Not satisfied	0	5 (17)
Psychological support  or counselling from  counsellor, therapist, social worker, or other support worker	Received	13 (23)	10 (33)
	Satisfied	6 (11)	5 (17)
	Not satisfied	0	1 (3)
Self-help booklet-based psychological support	Received*	12 (21)	14 (47)
	Satisfied	4 (7)	5 (17)
	Not satisfied	1 (2)	2 (7)
Internet-based psychological support or counselling	Received	12 (21)	6 (20)
	Satisfied	3 (5)	3 (10)
	Not satisfied	0	1 (3)
*p<.05, **p<.01, ***p<.001


Table 3: Use of antidepressants and psychotherapy by disease type
		IBDn=56	FGiDn=30
		n (%)
Have used antidepressants1		18 (34)*	17 (59)
The symptom antidepressants were prescribed for improved		12 (71) #	8 (57) #
Antidepressants-related side-effects		8 (44)* #	14 (87) #
Would you recommend antidepressants to other patients?	Yes	7 (30) #	4 (21) #
	No	5 (22) #	8 (42) #
	Unsure	11 (48) #	7 (37) #
Have used psychotherapy2		13 (25)	12 (43) 
The symptom psychotherapy was prescribed for improved		9 (64) #	11 (79) #
Would you recommend psychotherapy to other patients?	Yes	9 (53) #	11 (69) #
	No	1 (6) #	1 (6) #
	Unsure	7 (41) #	4 (25) #
*p<.05, # Please note these percentages are not of the whole sample but of the total number of users of antidepressants or psychotherapy, respectively 
1 Antidepressants used included (in the order of most common): sertraline, citalopram, mirtazapine, venlafaxine, ecitalopram, amitriptyline, paroxetine, fluoxetine, fluvoxamine, imipramine, olanzapamine (an antipsychotic), sodium valproate (an anticonvulsant)
2 Psychotherapy used included (in the order of most common): CBT, psychoanalysis, interpersonal; delivered as one-on-one sessions, in a group format, online, as a couple


Table 4: Offer of psychological or psychiatric help before and after the GI diagnosis by disease type
	Before GI diagnosis		After GI diagnosis	
		n (%)	
	IBDn=56	FGiDn=30	All Before	IBDn=56	FGiDn=30	All After
Was offered and accepted it	5 (9)	11 (37)*	16 (19)	8 (14)	9 (30)	17 (20)
Was offered but declined it	1 (2)	0 (0)	1 (1)	4 (7)	1 (3)	5 (6)
Wasn’t offered but I think it should have been offered	12 (21)	3 (10)*	15 (17)	18 (32)	5 (17)	23 (27)
Wasn’t offered and I don’t think it should have been offered	24 (43)	11 (37)*	35 (41)	16 (29)	11 (37)	27 (31)
Unsure	9 (16)	1 (3)*	10 (12)	6 (11)	2 (7)	8 (9)
*Fisher’s test p=.009



Table 5: Attitudes to various psychological/psychiatric services by disease type
	IBDn=56	FGiDn=30
	Mean (SD)	Median (IQR)	Mean (SD)	Median (IQR)
I would be willing to use antidepressants prescribed by a general practitioner, psychiatrist, or other doctor.	3.1 (1.3)	3 (2-4)	2.9 (1.5)	3 (1-4)
I would be willing to use psychotherapy or counselling in a one-on-one setting.	3.7 (0.9)	4 (3-4)	3.6 (1.4)	4 (2.7-5)
I would be willing to use psychotherapy or counselling in a group-based setting.	3.1 (0.9)	3 (2-4)	2.6 (1.5)	2.5 (1-4)
I would be willing to use an internet-based psychological support program.	3.3 (0.9)	3.5 (3-4)	2.9 (1.3)	3 (1.7-4)
I would be willing to use a printed booklet, with methods used by psychological support services, from home and in my own time.	3.5 (0.9)	4 (3-4)	3.3 (1.1)	4 (3-4)
If I were offered psychological support of any sort I would be likely to accept it.	3.5 (0.9)	4 (3-4)	3.1 (1.3)	3 (2-4)
1=strongly disagree; 2=disagree; 3=neither agree nor disagree; 4=agree; 5=strongly agree
IQR=inter-quartile range
SD=standard deviation








